

Neil Hawkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11992181/publications.pdf>

Version: 2024-02-01

18
papers

1,975
citations

687363

13
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

2574
citing authors

#	ARTICLE	IF	CITATIONS
1	The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. <i>Urology</i> , 2019, 127, 1-8.	1.0	14
2	Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2018, 36, 7-15.	3.3	11
3	An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data. <i>BMC Ophthalmology</i> , 2018, 18, 340.	1.4	10
4	â€˜Armâ€™-basedâ€™ parameterization for network metaâ€™ analysis. <i>Research Synthesis Methods</i> , 2016, 7, 306-313.	8.7	17
5	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. <i>BMC Pulmonary Medicine</i> , 2015, 15, 145.	2.0	14
6	Comparative effectiveness of antiviral treatment for hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 882-894.	1.6	17
7	The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2014, 3, 21.	5.3	4
8	A Comparison of National Guidelines for Network Meta-Analysis. <i>Value in Health</i> , 2014, 17, 642-654.	0.3	41
9	The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. <i>Experimental Hematology and Oncology</i> , 2013, 2, 5.	5.0	28
10	Surrogates, metaâ€™ analysis and costâ€™ effectiveness modelling: a combined analytic approach. <i>Health Economics (United Kingdom)</i> , 2012, 21, 742-756.	1.7	10
11	Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. <i>Value in Health</i> , 2011, 14, 429-437.	0.3	606
12	Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. <i>Value in Health</i> , 2011, 14, 417-428.	0.3	822
13	Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial. <i>BMC Medical Research Methodology</i> , 2010, 10, 54.	3.1	209
14	How Far Do You Go? Efficient Searching for Indirect Evidence. <i>Medical Decision Making</i> , 2009, 29, 273-281.	2.4	29
15	No Study Left Behind: A Network Meta-Analysis in Nonâ€™ Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data. <i>Value in Health</i> , 2009, 12, 996-1003.	0.3	37
16	Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?. <i>Value in Health</i> , 2006, 9, 244-252.	0.3	49
17	Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response. <i>Medical Decision Making</i> , 2005, 25, 511-519.	2.4	32
18	Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model. <i>Medical Decision Making</i> , 2005, 25, 493-510.	2.4	25